A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

October 21, 2025

Study Completion Date

October 21, 2025

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Romosozumab

Single-use prefilled syringe for SC injection.

Trial Locations (10)

110060

Sir Ganga Ram Hospital, New Delhi

110076

Apollo Hospital, New Delhi

400012

King Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College, Mumbai

411005

Sancheti Institute for Orthopedics and rehabilitation, Pune

560054

MS Ramaiah Medical College and Hospitals, Bangalore

632004

Christain Medical College, Vellore

380 007

Stavya Spine Hospital and Research Institute SSHRI, Ahmedabad

160 012

Post Graduate Institute of Medical Education and Research, Chandigarh

600 029

MGM Healthcare, Chennai

226 003

King Georges Medical University, Lucknow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06079476 - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. | Biotech Hunter | Biotech Hunter